Ruxolitinib Cream + Vehicle Cream
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Prurigo
Conditions
Prurigo
Trial Timeline
Mar 10, 2023 → Aug 13, 2025
NCT ID
NCT05755438About Ruxolitinib Cream + Vehicle Cream
Ruxolitinib Cream + Vehicle Cream is a phase 3 stage product being developed by Incyte for Prurigo. The current trial status is completed. This product is registered under clinical trial identifier NCT05755438. Target conditions include Prurigo.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06804811 | Phase 3 | Recruiting |
| NCT06959225 | Phase 3 | Recruiting |
| NCT06958211 | Phase 3 | Recruiting |
| NCT06548360 | Phase 3 | Recruiting |
| NCT06238817 | Phase 3 | Completed |
| NCT05764161 | Phase 3 | Completed |
| NCT05755438 | Phase 3 | Completed |
| NCT05635838 | Phase 2 | Completed |
| NCT05593432 | Phase 2 | Completed |
| NCT05593445 | Phase 2 | Completed |
| NCT04896385 | Phase 2 | Completed |
| NCT03745638 | Phase 3 | Completed |
| NCT03745651 | Phase 3 | Completed |
| NCT03099304 | Phase 2 | Completed |
Competing Products
20 competing products in Prurigo
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vixarelimab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Upadacitinib | AbbVie | Approved | 85 |
| Pimecrolimus + Hydrocortisone + Pimecrolimus | Novartis | Phase 2 | 52 |
| Rocatinlimab + Placebo | Amgen | Phase 3 | 76 |
| Abrocitinib | Pfizer | Phase 2 | 51 |
| Dupilumab SAR231893 (REGN668) | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Phase 3 | 76 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Ruxolitinib Cream 1.5% | Incyte | Phase 1 | 30 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| INCB054707 + Placebo | Incyte | Phase 2 | 49 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| CDX-0159 + Normal saline | Celldex Therapeutics | Phase 1 | 28 |
| barzolvolimab | Celldex Therapeutics | Phase 2 | 47 |
| nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 60 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 60 |
| Nalbuphine ER Tablets + Placebo Tablets | Trevi Therapeutics | Phase 2/3 | 60 |
| serlopitant + Placebo | Vyne Therapeutics | Phase 2 | 44 |